German Prices Might Give Big Pharma a Headache This Earnings Season -- Market Talk
Dow Jones2026/10/20 07:290728 GMT - Germany's austerity measures might loom over big pharmaceutical companies when they report third-quarter results over the coming weeks, RBC Capital Markets analysts say in a research note. Johnson & Johnson's results last week showed German price declines weighed on sales of the U.S. drugmaker's Darzalex cancer drug, and other companies have flagged potential hits, the analysts say. Merck, Johnson & Johnson, Novartis, AstraZeneca and Roche have a higher exposure to Germany and oncology sales, according to RBC. The Stoxx Europe 600 Health Care index rises 0.9%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
October 20, 2026 03:29 ET (07:29 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Oppenheimer says Jefferies' share price remains undervalued
UK unemployment rate unexpectedly drops to 4.7%! Positive employment data ahead of the budget boosts expectations for a Bank of England rate hike in November
The UK unemployment rate has dropped to 4.7%, with a surprising increase in employment and accelerating wage growth, raising expectations for a Bank of England rate hike in November.
Crypto prices
More
